X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Glenmark gains at Fulford’s cost - Views on News from Equitymaster
 
 
  • PRINT
  • E-MAIL
  • FEEDBACK
  • A  A  A
  • May 16, 2000

    Glenmark gains at Fulford’s cost

    The dermatology segment (which deals with skin infections) of the pharmaceutical formulation industry has been witnessing a heavy dose of competition. While the overall formulation segment has grown at 9.8% for FY2000, this segment has grown at only 8.2%.

    While the market leader Glaxo seems to have slightly increased its market share, a relatively smaller company, Glenmark Pharmaceuticals seems to be a major gainer at the cost of its bigger rivals Fulford and Ranbaxy. This seems to be primarily due to the marketing push the company has been given to its products particularly Candid, its dermatological brand which seems to be following in Glaxo’s footsteps.

    As per the ORG data (see table) Glaxo remains the market leader by far, with a 16.9% market share in the dermatology segment. This is due to the fact that its Betnovate range of formulations have achieved near OTC status (Over the Counter) despite being prescription brands.

      Value (Rs m) Market Share Growth
    Overall Value 7,549 100.0% 8.2%
    Glaxo–Wellcome 1,278 16.9% 8.9%
    Fulford 649 8.6% -7.3%
    Ranbaxy–Croslands 471 6.2% 3.0%
    Glenmark Pharma 434 5.8% 26.2%

    Source ORG RSA Mar 2000

    The surprise has however been an over 25% growth for Candid. Though one can argue that Glenmark’s growth has been from a much lower base (since Glaxo’s dermatological revenues almost equal the entire revenues of the Glenmark) this just shows the importance of brand building and establishing mind recall for pharma products and the benefits it yields during a slowdown in the industry.

     

     

    Equitymaster requests your view! Post a comment on "Glenmark gains at Fulford’s cost". Click here!

      
     

    More Views on News

    Glenmark Pharma: Lower Zetia Sales leads to Subdued Growth (Quarterly Results Update - Detailed)

    May 18, 2017

    Base price erosion in the US and lower Zetia sales impacts profits.

    Glenmark: Zetia Generics Boost Growth (Quarterly Results Update - Detailed)

    Feb 15, 2017

    Glenmark has announced its 3QFY16 results. The company has reported 41% YoY growth in net sales and 143.2% YoY increase in net profits. Here is our analysis of the results.

    Glenmark: High Costs hit the Bottom line (Quarterly Results Update - Detailed)

    Nov 8, 2016

    Glenmark has announced its 2QFY16 results. The company has reported 15.7% YoY growth in net sales and 3.5% YoY increase in net profits. Here is our analysis of the results.

    Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

    Aug 14, 2017

    A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

    Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

    Aug 14, 2017

    GST impact coupled with price erosion in US leads to lower profits for the quarter.

    More Views on News

    Most Popular

    Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

    Aug 7, 2017

    The data tells us quite a different story from the one the government is trying to project.

    A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

    Aug 10, 2017

    Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

    Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

    Aug 8, 2017

    Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

    Signs of Life in the India VIX(Daily Profit Hunter)

    Aug 12, 2017

    The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

    7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

    Aug 7, 2017

    Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

    More
    Copyright © Equitymaster Agora Research Private Limited. All rights reserved.
    Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

    LEGAL DISCLAIMER: Equitymaster Agora Research Private Limited (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA or Canada, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.

    SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

    Equitymaster Agora Research Private Limited. 103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
    Telephone: +91-22-61434055. Fax: +91-22-22028550. Email: info@equitymaster.com. Website: www.equitymaster.com. CIN:U74999MH2007PTC175407
     

    Become A Smarter Investor In
    Just 5 Minutes

    Multibagger Stocks Guide 2017
    Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
    We will never sell or rent your email id.
    Please read our Terms

    GLENMARK PHARMA SHARE PRICE


    Aug 18, 2017 (Close)

    TRACK GLENMARK PHARMA

    • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
    • Add To MyStocks

    MORE ON GLENMARK PHARMA

    GLENMARK PHARMA - LUPIN LTD COMPARISON

    Compare Company With Charts

    COMPARE GLENMARK PHARMA WITH

    MARKET STATS